| Name | Title | Contact Details |
|---|
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
For more than 100 years we`ve been 100 percent dedicated to kids. Children’s Healthcare of Atlanta, a not-for-profit organization, is dedicated to making kids better today and healthier tomorrow. Our specialized care helps children get better faster and live healthier lives. Managing more than 850,000 patient visits annually at three hospitals and 27 neighborhood locations, Children’s is the largest healthcare provider for children in Georgia and one of the largest pediatric clinical care providers in the country. Children’s offers access to more than 60 pediatric specialties and programs and is ranked among the top children’s hospitals in the country by U.S.News & World Report. With generous philanthropic and volunteer support, Children’s has impacted the lives of children in Georgia, the United States and throughout the world.
Biodenix Technologies Inc. is a Richmond, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The University of Vermont Medical Center is part of a six-hospital network serving patients and their families in Vermont and northern New York. We`re not just caregivers and staff - we`re your friends and neighbors, offering expertise, kind words and compassionate care when and where you need them. We are dedicated to providing you with the best medical care possible. The University of Vermont Medical Center, along with the Robert Larner M.D. College of Medicine The University of Vermont and College of Nursing and Health Sciences, is one of 138 academic medical centers in the country. Through The University of Vermont Health Network and collaborative relationships throughout Vermont and northern New York, we are able to provide the highest quality care, informed by academic research, to patients throughout our region. The UVM Medical Center, along with its three founding organizations, The University of Vermont College of Medicine and College of Nursing and Health Sciences, share a rich history dating back to the 1800s. The UVM Medical Center is committed to the development of an Integrated Delivery System which provides high value health care to the communities we serve and enhances our academic mission. Our mission is to improve the health of the people in the communities we serve by integrating patient care, education, and research in a caring environment.
IGeneX Inc. is a Reference Laboratory specializing in State-of-the-Art Clinical and Research Testing for Lyme Disease and Associated Tick-borne Diseases.